LBRX · LB Pharmaceuticals Inc
LB Pharmaceuticals Inc (LBRX)
What's happening
- LBRX is down 3.94% today, trading at $39.36. — Live quote
- Volume today (16,402) is well below its 3-month average of 373,080. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-1.71 actual vs. $-0.82 estimated (-108.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $978.2M | $703.0M | $92.3M | — | — |
| P/E | -12.37 | -21.44 | -3.31 | — | — |
| Price/Book | 2.94 | 1.86 | 0.30 | — | — |
| ROE | -23.80% | -8.66% | -9.00% | — | — |
| ROA | -21.87% | -8.33% | -8.70% | — | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +145.2%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LBRX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Net income | -$51.6M | -$19.1M | -$3.6M | -$4.9M | -$5.3M | -$14.2M | -$27.6M | -$16.2M |
| EPS (diluted) | $-1.71 | $-0.67 | $-0.61 | $-13.58 | $-14.79 | $-39.49 | — | — |
| EPS (basic) | $-1.71 | $-0.67 | $-0.61 | $-13.58 | $-14.79 | $-39.49 | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $361.7M | $393.5M | $312.9M | $320.7M | — | — | $33.5M | — |
| Total liabilities | $29.3M | $14.8M | $11.6M | $10.5M | — | — | $13.8M | — |
| Stockholders' equity | $332.3M | $378.7M | $301.3M | $310.2M | -$103.9M | -$99.3M | -$94.6M | -$91.5M |
| Total current assets | $355.3M | $389.1M | $308.4M | $316.4M | — | — | $28.9M | — |
| Total current liabilities | $23.6M | $10.9M | $7.4M | $6.6M | — | — | $8.1M | — |
| Cash & equivalents | $283.1M | $320.7M | $250.2M | $269.7M | — | — | $23.0M | — |
| Marketable securities (current) | $44.7M | $45.0M | $45.0M | $44.7M | — | — | $5.0M | — |
| Property, plant & equipment | $2.2M | $1.5M | $1.6M | $1.6M | — | — | $1.9M | — |
| Accounts payable | $3.5M | $7.1M | $2.1M | $2.6M | — | — | $2.3M | — |
| Accrued liabilities | $19.2M | $3.1M | $4.6M | $3.3M | — | — | $5.3M | — |
| Common stock & paid-in capital | $3.0K | $3.0K | $3.0K | $114.3M | — | — | $1.0K | — |
| Retained earnings | -$200.2M | -$148.6M | -$129.5M | -$118.1M | — | — | -$104.3M | — |
| Accumulated other comprehensive income (loss) | $186.0K | $208.0K | $168.0K | -$53.0K | — | — | $111.0K | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$37.6M | -$23.3M | -$18.1M | -$3.4M | -$5.6M | -$8.1M | -$5.7M | -$47.4M |
| Investing cash flow | $89.0K | -$32.0K | -$40.0K | -$44.8M | $9.0K | $5.0M | $13.5M | $9.7M |
| Financing cash flow | -$19.0K | $93.8M | -$1.2M | $303.7M | $0 | $0 | $0 | $38.3M |
| Free cash flow | -$38.0M | -$23.3M | -$18.1M | -$3.4M | -$5.6M | -$8.1M | -$5.9M | -$47.9M |
| Capital expenditures | $363.0K | $32.0K | $40.0K | $0 | -$9.0K | $21.0K | $238.0K | $531.0K |
| Depreciation & amortization | — | — | $321.0K | — | — | — | $91.0K | — |
| Share-based compensation | $4.9M | $2.6M | $2.3M | $881.0K | $335.0K | $634.0K | $2.3M | $813.0K |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Purchases of investments | $9.7M | — | $0 | $44.8M | $0 | — | $0 | $29.7M |
| Sales/maturities of investments | — | — | $2.5M | — | — | — | $23.6M | — |
Income statement
| Line item | Dec '25 | Dec '24 |
|---|---|---|
| Net income | -$25.2M | -$63.1M |
| EPS (diluted) | $-3.13 | $-176.15 |
| EPS (basic) | $-3.13 | $-176.15 |
Balance sheet
| Line item | Dec '25 | Sep '25 | Dec '24 | Dec '23 |
|---|---|---|---|---|
| Total assets | $312.9M | — | $33.5M | — |
| Total liabilities | $11.6M | — | $13.8M | — |
| Stockholders' equity | $301.3M | — | -$94.6M | -$34.5M |
| Total current assets | $308.4M | — | $28.9M | — |
| Total current liabilities | $7.4M | — | $8.1M | — |
| Cash & equivalents | $250.2M | — | $23.0M | — |
| Marketable securities (current) | $45.0M | — | $5.0M | — |
| Property, plant & equipment | $1.6M | — | $1.9M | — |
| Accounts payable | $2.1M | — | $2.3M | — |
| Accrued liabilities | $4.6M | — | $5.3M | — |
| Common stock & paid-in capital | $3.0K | $114.3M | $1.0K | — |
| Retained earnings | -$129.5M | — | -$104.3M | — |
| Accumulated other comprehensive income (loss) | $168.0K | — | $111.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 |
|---|---|---|
| Operating cash flow | -$35.2M | -$53.1M |
| Investing cash flow | -$39.9M | $23.2M |
| Financing cash flow | $302.6M | $38.3M |
| Free cash flow | -$35.3M | -$53.8M |
| Capital expenditures | $52.0K | $769.0K |
| Depreciation & amortization | $321.0K | $91.0K |
| Share-based compensation | $4.2M | $3.1M |
| Deferred income taxes | $0 | $0 |
| Purchases of investments | $44.8M | $29.7M |
| Sales/maturities of investments | $2.5M | $23.6M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LBRX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-09-12 to 2025-09-12
Recent transactions
- Most recent: Deep Track Biotechnology Master Fund, Ltd. (Reporting person) — Derivative conversion of 686,138 shares on 2025-09-12.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | Reporting person | Derivative conversion | 2025-09-12 | 686,138 |
| Pontifax Management 4 G.P. (2015) Ltd. | Reporting person | Derivative conversion | 2025-09-12 | 411,681 |
| Nussbaum Ran | Reporting person | Derivative conversion | 2025-09-12 | 411,681 |
| Vida Ventures GP III, L.L.C. | Reporting person | Derivative conversion | 2025-09-12 | 547,648 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. | Reporting person | Derivative conversion | 686,138 | — |
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. | Reporting person | Open market purchase | 2,000,000 | $15.00 |
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. | Reporting person | Open market purchase | 666,666 | $15.00 |
| 2025-09-12 | Pontifax Management 4 G.P. (2015) Ltd. | Reporting person | Derivative conversion | 411,681 | — |
| 2025-09-12 | Pontifax Management 4 G.P. (2015) Ltd. | Reporting person | Open market purchase | 1,000,000 | $15.00 |
| 2025-09-12 | Nussbaum Ran | Reporting person | Derivative conversion | 411,681 | — |
| 2025-09-12 | Nussbaum Ran | Reporting person | Open market purchase | 1,000,000 | $15.00 |
| 2025-09-12 | Vida Ventures GP III, L.L.C. | Reporting person | Derivative conversion | 547,648 | — |
| 2025-09-12 | Vida Ventures GP III, L.L.C. | Reporting person | Derivative conversion | 1,262 | — |
| 2025-09-12 | Vida Ventures GP III, L.L.C. | Reporting person | Open market purchase | 332,566 | $15.00 |
| 2025-09-12 | Vida Ventures GP III, L.L.C. | Reporting person | Open market purchase | 767 | $15.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:55 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-09 | View on SEC.gov → |
| 2026-09-15 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-09-03 | 8-K | 2026-09-03 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-07-30 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-07-22 | 8-K | 2026-07-22 | View on SEC.gov → |
| 2026-06-10 | 8-K | 2026-06-08 | View on SEC.gov → |
| 2026-06-09 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-03 | View on SEC.gov → |
Recent news
Headlines about LBRX (LB Pharmaceuticals Inc). Links open the publisher — we don’t host full articles.
-
Stifel reiterates Buy rating on LB Pharmaceuticals stock at $53
Investing.com · 2026-10-21 -
LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $57.40 According to Analysts
MarketBeat · 2026-10-20 -
LBRX Jan 2027 35.000 call (LBRX270115C00035000) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada · 2026-10-16 -
LB Pharmaceuticals (NASDAQ:LBRX) Shares Gap Up - What's Next?
MarketBeat · 2026-10-16 -
LBRX Jan 2027 35.000 call (LBRX270115C00035000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16 -
LB Pharmaceuticals to Participate in Upcoming Investor Events
Yahoo · 2026-10-15 -
LB Pharmaceuticals (NASDAQ:LBRX) Stock Jumps 8.8% - Should You Buy?
MarketBeat · 2026-10-15 -
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
Benzinga · 2026-10-15
No headlines in this category right now — try “All”.